MOESM3 of Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Teofila Seremet
Yanina Jansen
Simon Planken
Hassan Njimi
MĂŠlanie Delaunoy
Hakim El Housni
Gil Awada
Julia Schwarze
Marleen Keyaerts
Hendrik Everaert
Danielle Lienard
VĂŠronique Marmol
Pierre Heimann
Bart Neyns
10.6084/m9.figshare.9777104.v1
https://springernature.figshare.com/articles/journal_contribution/MOESM3_of_Undetectable_circulating_tumor_DNA_ctDNA_levels_correlate_with_favorable_outcome_in_metastatic_melanoma_patients_treated_with_anti-PD1_therapy/9777104
Additional file 3: Table S1. Longitudinal monitoring of patients with progressive disease exclusively in the central nervous system. Table S2. Absolute values of longitudinal monitoring of patients with >â500 copies of mutated ctDNA/ml of plasma at baseline and/or at week 3.
2019-09-06 04:32:19
Translational research
Liquid biopsy
Circulating tumor DNA
Monitoring
Immunotherapy
Metastatic melanoma
BRAF/NRAS mutations monitoring